Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

545.53
+3.010.55%
Post-market: 545.600.0700+0.01%19:40 EDT
Volume:709.16K
Turnover:388.17M
Market Cap:58.90B
PE:13.84
High:552.98
Open:543.44
Low:542.50
Close:542.52
Loading ...

Regeneron Shares Set for Worst Day Since 2011; Last Down 17.8%

THOMSON REUTERS
·
30 May

Regeneron Shares Fall 15.8%; Co and Sanofi's Drug Itepekimab Met Main Goal in One Out of Two Late-Stage Trials

THOMSON REUTERS
·
30 May

US STOCKS-Wall St set for lower open as Trump says China violated tariff terms

Reuters
·
30 May

Sector Update: Health Care Stocks Fall Pre-Bell Friday

MT Newswires Live
·
30 May

Wells Fargo Downgrades Regeneron Pharmaceuticals to Equal Weight From Overweight, $580 Price Target

MT Newswires Live
·
30 May

Exchange-Traded Funds Mixed, Equity Futures Lower Pre-Bell Friday Amid US Tariff Reinstatement Decision

MT Newswires Live
·
30 May

Regeneron Stock (REGN) Retreats as Lung Disease Drug Data Disappoints

TIPRANKS
·
30 May

Regeneron Shares Slide On Mixed Trial Data For Smoker's Lung Drug

Reuters
·
30 May

BUZZ-Regeneron slumps after closely watched smoker's lung drug fails trial

Reuters
·
30 May

Regeneron Shares Extend Premarket Fall; Last Down 11.7%

THOMSON REUTERS
·
30 May

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

Dow Jones
·
30 May

Regeneron Shares Fall 8.2% Premarket; Co and Sanofi's Drug Itepekimab Met Main Goal in One Out of Two Late-Stage Trials

THOMSON REUTERS
·
30 May

Regeneron: Strong Financial Performance and Strategic Initiatives Drive Buy Rating with USD700 Target Price

TIPRANKS
·
30 May

BRIEF-Sanofi's AERIFY-1 Met Primary Endpoint, AERIFY-2 Did Not

Reuters
·
30 May

Sanofi Announces Mixed Results from Phase 3 Studies of Itepekimab for COPD Treatment

Reuters
·
30 May

Regeneron Pharmaceuticals Inc - Regeneron and Sanofi Are Assessing This Data and Will Discuss Next Steps With Regulatory Authorities

THOMSON REUTERS
·
30 May

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

GlobeNewswire
·
30 May

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
30 May

Regeneron Pharmaceuticals' Itepekimab Likely to Open 'Large' Market Opportunity, RBC Says

MT Newswires Live
·
29 May

Telesis Bio Secures Licensing Deal with Regeneron for On-Site DNA Synthesis Platform

Reuters
·
28 May